Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 13 (final count)
- Started
- Feb 28, 2024
- Main results expected
- Jun 17, 2025
- Fully finished
- Jun 17, 2025
- Results posted
- Jun 5, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1
Measured over: During the first two 14-day cycles (Up to approximately 28 days)
Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2
Measured over: Up to approximately 12 months
Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2
Measured over: Up to approximately 9 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06242691 · record last updated 2026-06-05 · checked 2026-11-09 15:47 UTC